Gyeonggi, South Korea
Gyeonggi, South Korea

Time filter

Source Type

News Article | October 28, 2016
Site: www.marketwired.com

CARLSBAD, CALIFORNIA--(Marketwired - Oct. 25, 2016) - Aurora Spine Corporation (TSX VENTURE:ASG) announced today that it will be participating at the 2016 North American Spine Society ("NASS") Annual Meeting, October 26 - 28, 2016 at the Boston Convention and Exhibition Center Boston, Massachusetts at Booth 1302. The North American Spine Society is a global multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical, value and evidence based spine care. Aurora Spine will be showcasing its Screwless Procedure™ and highlighting its latest fusion technologies, including the recently patented ZIP® MIS Interspinous fusion systems. The Screwless Procedure product portfolio consists of the innovative ZIP® ISP Product Line, TiNano® Interbody cages, Biologics, and Surgical Tools. All Aurora Spine products are pre-packaged sterile to provide the best products possible for both surgeons and patients alike. "Aurora's modern spine technology is changing spine surgery for the benefit of patients worldwide," said Trent J. Northcutt, President and CEO of Aurora Spine. "We are excited to demonstrate the Screwless Procedure™ featuring our TiNano® MIS titanium coated interbody cages, our recently patented innovative ZIP® MIS Interspinous fusion systems, and the Compass 4D™ retractor system, all designed to improve spine patient outcomes, drive continued surgeon interests and provide benefits that deliver value to hospitals and patients. We look forward to demonstrating our cutting-edge portfolio to spine surgeons and distributors attending the world's largest spine exhibition in Boston, Massachusetts." Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine continues to position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies. Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company's commitment to - Simplifying the Complex. This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.


News Article | February 15, 2017
Site: www.prweb.com

Early clinical results presented by surgeons at the 2016 annual meeting of the North American Spine Society (NASS)1 demonstrate high fusion rates at 6 months and beneficial clinical outcomes, for patients in the majority of cases, when PEEK-OPTIMA™ HA Enhanced is used for interbody-fusion devices. The implantable high-performance polymer, from Invibio Biomaterial Solutions, uniquely combines PEEK-OPTIMA, the principal PEEK-based biomaterial with over 15 years of proven history in clinical use, and hydroxyapatite (HA), a well-known osteoconductive material that enhances bone apposition, and is fully integrated. Previous studies by Invibio have highlighted that enhancing bone apposition on all surfaces of an interbody-fusion device may offer better integration and improved potential for spinal fusion. “The findings on first clinical cases for PEEK-OPTIMA HA Enhanced presented at the NASS 2016 annual meeting are demonstrating the Invibio goal of providing solutions that have the potential to improve clinical outcomes and advance bone apposition in interbody-fusion procedures2,” said John Devine, Invibio Medical Business Director. “In addition, the results presented confirm that the partnerships we have forged with device manufacturers and surgeons are pioneering approaches that are leading to positive results for patients.” During NASS, Timothy Bassett, MD, of SouthEastern Spine Specialists, Tuscaloosa, AL, presented his ‘Early Clinical Experience with a PEEK-OPTIMA HA Enhanced Device for Lumbar Fusion’. The 1-2 level TLIF (Transforaminal Lumbar Interbody Fusion) procedure utilized the EVOS HA Device, from Cutting Edge Spine, intended for use in skeletally mature patients with Degenerative Disc Disease (DDD) of the lumbar spine, plus autograft bone with posterior instrumentation. No biologics were used in this series of nine patients. The clinical results were evaluated for pain on the Visual Analogue Scale (VAS), opiate usage, neurological function, re-operations and complications. Fusion results were evaluated using anteroposterior (AP) and lateral X-rays at six weeks and 12 weeks, and a CT scan at six months. Dr Bassett concluded, “Very rapid visible bone fusion occurred in the interbody region in six weeks, according to plain radiographs, with correspondingly good clinical results including no neurologic consequences beyond 6 weeks, no implant migrations, no subsidence, and no pseudoarthroses. More importantly, 9/10 fusions were definitively solid on 6 month CT scan with autograft bone, despite some challenging patients. The one that didn’t show complete fusion was progressing to fusion and used one pack of tobacco daily, both pre- and post-operative, contributing to the fusion challenge. Brad Prybis, MD at Carrollton Orthopaedic Clinic, Carrollton, GA, assessed use of the Talos®-C (HA) Cervical Interbody Fusion Device, from Meditech Spine, in patients who underwent 2-3 level anterior cervical discectomy and fusion (ACDF). Clinical (pain and neurological function) and radiographic outcomes were assessed at six months post-operatively. Arm pain was resolved in all 8 patients; in 5/8 patients neck pain was resolved and improved in 7/8 patients. Furthermore, all 8 patients demonstrated improved neurological function, with residual numbness in 3/8, and residual weakness in 1/8 patients. 17/17 levels were fused 6 months post-operatively. Commenting on the findings, Dr Prybis said, “The Talos-C (HA), a next-generation interbody-fusion device made from PEEK-OPTIMA HA Enhanced polymer, provided clinical and radiographic results as good as or better than traditional PEEK interbody devices, with consistently good outcomes at early time points we are looking forward to the results of further clinical studies.” PEEK-OPTIMA HA Enhanced biomaterial offers all the clinical advantages of PEEK-OPTIMA Natural including a modulus similar to cortical bone, reduced stress shielding and artifact-free imaging that allows for clear fusion assessment. Developed by Invibio, a leading provider of biomaterial solutions, this innovative high performance polymer for spinal fusion implants eliminates the extra processing time and expense of alternative bone on-growth technologies, such as coatings. Implant devices made of the novel PEEK-OPTIMA HA Enhanced have already been cleared by regulatory bodies in both the US (FDA 510(k) clearance) and Europe (CE mark approval). For more information about PEEK-OPTIMA HA Enhanced, please visit http://www.invibiospine.com 2. Study evaluated the in vivo response to PEEK-OPTIMA Natural, PEEK-OPTIMA HA Enhanced and allograft in a cervical spine fusion model in sheep. Data are on file at Invibio. This has not been correlated with human clinical experience. The case study data and testimonials presented here have been provided by practicing orthopedic surgeons. Their views and experiences are their own and do not necessarily reflect those of others. “Invibio” disclaims any liabilities or loss in connection with the information herein. INVIBIO™, PEEK-OPTIMA™, INVIBIO BIOMATERIAL SOLUTIONS™ are trademarks of Victrex plc or its group companies. About Invibio Biomaterial Solutions Invibio, a Victrex plc company, is a global leader in providing high performance biomaterial solutions to medical device manufacturers. The company provides PEEK-OPTIMA™ polymers, advanced technical research and support and manufacturing of components for spine, trauma and orthopaedic medical segments for the development of long implantable medical devices. Today, Invibio’s PEEK-OPTIMA™ polymers are used in more than five million implanted devices worldwide. About Victrex Victrex, headquartered in the UK, is an innovative world leader in high performance polymer solutions focused on the Aerospace, Automotive, Electronics, Energy and Medical markets. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years’ experience, we are delivering leading edge solutions to shape future performance for our customers and our markets, and to drive value for our shareholders. Find out more at http://www.victrexplc.com


News Article | February 15, 2017
Site: www.marketwired.com

WASHINGTON, DC--(Marketwired - February 15, 2017) - The American Land Title Association (ALTA), the national trade association of the land title insurance and real estate settlement industry, sent a letter to the National Association of Secretaries of State (NASS) offering support of efforts to promote the understanding of remote electronic notarizations. In the letter, ALTA offered eight suggestions to help guide the development of clear statutes, regulations and standard practices that authorize and recognize remote electronic notarization. The guidance is necessary to give certainty that remote and video notarizations will be accepted as valid transactions by county recorders, state courts and bankruptcy trustees. "The title insurance and settlement industry seeks assurance that a remotely electronically notarized document will receive the same legal certainty, and provide effective constructive notice, under state law as a traditional, wet-signed, face-to-face, personal appearance notarization," said Michelle Korsmo, ALTA's chief executive officer. "Though states have long accepted traditional notarizations conducted in other states, it is currently unclear as to whether remote electronic notarizations will receive the same treatment." ALTA believes the following elements should be included in remote electronic notarization statutes: For more, you may download ALTA's letter. The American Land Title Association, founded in 1907, is the national trade association representing more than 6,200 title insurance companies, title and settlement agents, independent abstracters, title searchers, and real estate attorneys. With offices throughout the United States, ALTA members conduct title searches, examinations, closings, and issue title insurance that helps protect the property rights of millions of American homebuyers every year.


Provides Physical Medicine Rehabilitation Services to Patients in the South Cobb Area including Non-surgical Spine and Functional Medicine ​​​OrthoAtlanta is pleased to welcome board-certified physiatrist, Deitrick L. Cox, M.D., to its orthopedic and sports medicine practice in Austell, bringing expertise in physical medicine and rehabilitation (PM&R) to patients in the greater South Cobb area including Austell, Lithia Springs, Mableton, and Smyrna. Dr. Cox provides non-surgical orthopedic care, including non-surgical spine, musculoskeletal medicine and functional medicine to patients suffering muscular, nerve, joint, and tendon injuries. Dr. Cox’s specialty areas of interest include precision-based treatments such as fluoroscopic-guided interventional spinal injections, including, but not limited to, epidural and facet injections, radiofrequency neurotomy, spiral neuromodulation, sacroiliac joint injections, and hip injections. Dr. Cox is also skilled at ultrasound-guided peripheral joint injections, regenerative medicine, electrodiagnostic medicine / electromyography (EMG), and myofascial trigger point injections. Dr. Cox believes in partnering with his patients to develop treatment plans to significantly reduce, if not eliminate, pain and optimize physical function. As expressed by Dr. Cox, “I seek to maintain the perfect balance between teaching and treating when serving patients. My philosophy of care includes listening to the patient, educating the patient, and collaborating with the patient to develop the best treatment plan for them.” Prior to joining OrthoAtlanta, Dr. Cox had his own company providing procedure-based physiatric and pain management procedures and services to orthopedic, physical medicine and pain management practices within the greater Atlanta area. “We are excited to welcome Dr. Deitrick Cox to OrthoAtlanta Austell to provide non-surgical patient care,” stated OrthoAtlanta Medical Director, Dr. Michael Behr. “Dr. Cox combines a passion for orthopedics, physics, and procedure-based treatment plans that help restore patient functionality to return them to the things they love doing.” Dr. Deitrick Cox graduated from Amherst College, Amherst, MA, completing both a Bachelor of Science degree in Religion and pre-medical studies. Awarded a merit-based medical scholarship, Dr. Cox received his Doctor of Medicine degree at Morehouse School of Medicine in Atlanta, GA. He completed his Internship at Harvard Medical School, Cambridge Health Alliance, in Cambridge, MA and medical residency in Physical Medicine and Rehabilitation at Emory University in Atlanta, GA. Medical professionals influencing Dr. Cox’s decision to pursue a medical career and specialty in physiatry include orthopedic surgeon, J. Mandume Kerina of Leesburg, Florida, and PM&R physicians, Dr. Rosalind Bass and Dr. Lisa Merritt. Dr. Cox is a member of the American Academy of Physical Medicine and Rehabilitation, the National Medical Association and the North American Spine Society (NASS). Dr. Cox is a certified provider with the United States Department of Labor (DOL), Office of Federal Workers’ Compensation, and can accept both Federal and non-government occupational and work-related injury cases as well as personal injury cases. Dr. Cox and his wife have a three-year old son and another child on the way. He enjoys travel and sports including football, basketball and track & field. Appointments with Dr. Deitrick Cox may be requested at OrthoAtlanta Austell, 770-944-3303. About OrthoAtlanta OrthoAtlanta is one of the largest orthopaedic and sports medicine practices in the greater Atlanta, Georgia area. With 39 physicians serving in 12 offices, the physician-owned practice is dedicated to providing the highest level of patient care for injury or deformity of muscles, joints, bones and spine. OrthoAtlanta offers convenient accessibility to a full range of musculoskeletal surgeons, specialists and patient services including on-site physical therapy, pain management care, six MRI imaging centers and workers’ compensation coordination. OrthoAtlanta Surgery Centers in Austell and Fayetteville provide cost-effective, same-day surgical procedures in an accredited outpatient center. Comprehensive operative and non-operative musculoskeletal care and expertise includes sports medicine, arthroscopic surgery, hip replacement, knee replacement, neck and spine surgery, elbow and shoulder surgery, foot and ankle surgery, pain management, arthritis treatment, general orthopedics, work related injuries and acute orthopaedic urgent care.  Learn more at www.OrthoAtlanta.com. For additional information, please contact Pat Prosser, Public Relations Manager, at OrthoAtlanta, 678-996-7254, or via email pprosser@OrthoAtlanta.com.


News Article | February 15, 2017
Site: www.marketwired.com

ATLANTA, GA--(Marketwired - Feb 15, 2017) - Medovex Corp. ( : MDVX), a developer of medical technology products, today announced that the Company successfully completed its final CE Mark audit meeting. The review of the Company's DenerveX™ System was conducted February 7-9, 2017 by LNE/GMED, a French-based Notified Body firm. This audit is required to demonstrate compliance with the regulatory requirements to achieve CE Mark approval. Patrick Kullmann, Medovex President and COO, stated, "We're very pleased to have completed our certification audit of the DenerveX System February 7-9, 2017 at the Company's Atlanta based offices. Our in-house development team, along with several representatives from our world-class suppliers and consultants, contributed extensively during this process due to their vast expertise in R&D, manufacturing, electro-surgery, regulatory, quality, and sterilization processes." Kullmann further stated, "Upon successfully completing this audit, the CE certificate would generally be expected to be issued paving the way to the future launch of the DenerveX System in the EU and other countries which accept the CE Mark." Previously on January 3, 2017, the Company announced it had successfully received certification of compliance for its DenerveX System from SGS S.A. a Swiss based multinational testing and certification firm. Compliance testing included electrical safety testing for US, Canada and the European Union. Prior to that on November 3, 2016, the Company announced that it held a successful cadaver lab during NASS 2016. Medical advisory board members Martin Deeg, MD from Stuttgart, Germany, Vik Kapoor, MD from Manchester, England, as well as Gabriel Davila, MD from Colombia, Latin America, highlighted the DenerveX System. Thirty spine surgeons from Europe and Latin America attended the lab, both experiencing and using the device. Jarrett Gorlin, Medovex CEO, commented, "I'm very proud of our team and how they prepared for and handled this important event. Together, we have spent countless hours in anticipation of meeting with representatives of LNE/GMED. Although a date has not been provided for the anticipated receipt of the CE certificate or the launch of the product, we believe we remain well on our way to completing the final regulatory step in the process of achieving CE Marking." The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator, both designed to be less invasive with faster recovery time than current surgical treatment options, and is expected to provide for a longer lasting treatment solution while offering potential savings to the health care system. DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available. About Medovex Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com Safe Harbor Statement Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


ATLANTA, GA--(Marketwired - Feb 27, 2017) -  Medovex Corp. ( : MDVX), a developer of medical technology products, today announced that on Friday, February 24, 2017, the Company filed a Form 8K with the Securities and Exchange Commission affirmatively stating its current compliance with NASDAQ's stockholder equity requirement. From the 8K, "The Company affirmatively states that as of the date of this Current Report on Form 8-K, that it has stockholders' equity in excess of $2,500,000 based on the culmination of the aforementioned transactions." On February 21, 2017, the Company provided the following corporate update. On February 15th, 2017, the Company announced that it had successfully completed its final CE Mark audit meeting. The review of the Company's DenerveX™ System was conducted February 7-9, 2017 by LNE/GMED, a French-based Notified Body firm. This audit is required to demonstrate compliance with the regulatory requirements to achieve CE Mark approval. On February 9, 2017, Medovex Corporation announced it had entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold an aggregate of 2,905,770 shares and 1,452,885 warrants for gross proceeds of $3,022,000. Each warrant has an initial exercise price of $1.50 per share, subject to adjustment, and is initially exercisable for a period of five years from the date of issuance. Certain officers and directors of Medovex participated in the financing. In conjunction with the closing of the transaction, the Company's previously issued $1,150,000 of senior secured promissory notes has been converted to 165,864 shares of Common Stock and 9399 shares of Series A Preferred Stock and warrants on the same terms as the other investors. Each share of Series A Preferred Stock is convertible into 100 shares of common stock and effectively has the same price of $1.04 per share of Common Stock. In addition to the recent financing transaction, in a transaction filed with the SEC on a Form 8k on December 6, 2016, insiders Jesse Crowne, Steve Gorlin and a third party, completed the purchase of 571,429 shares of the Company's common stock at above then market pricing of $1.75 per share, such that the Company received an aggregate of $1,000,000. On January 3, 2017, the Company announced it had successfully received certification of compliance for its DenerveX System from SGS S.A., a Swiss based multinational testing and certification firm. Compliance testing included electrical safety testing for US, Canada and the European Union. Prior to that on November 3, 2016, the Company announced that it held a successful cadaver lab during NASS 2016. Medical advisory board members Martin Deeg, MD from Stuttgart, Germany, Vik Kapoor, MD from Manchester, England, as well as Gabriel Davila, MD from Colombia, Latin America, highlighted the DenerveX System. Thirty spine surgeons from Europe and Latin America attended the lab, both experiencing and using the device. The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available. About Medovex Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com Safe Harbor Statement Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


News Article | February 21, 2017
Site: www.marketwired.com

Recent Completion of Final CE Mark Audit and Financing with Insider Participation Positions Company for 2017 ATLANTA, GA--(Marketwired - Feb 21, 2017) - Medovex Corp. ( : MDVX), a developer of medical technology products, today provided the following corporate update. On February 15th, 2017, the Company announced that it had successfully completed its final CE Mark audit meeting. The review of the Company's DenerveX™ System was conducted February 7-9, 2017 by LNE/GMED, a French-based Notified Body firm. This audit is required to demonstrate compliance with the regulatory requirements to achieve CE Mark approval. Patrick Kullmann, Medovex President and COO, stated, "Upon successfully completing this audit, the CE certificate would generally be expected to be issued paving the way to the future launch of the DenerveX System in the EU and other countries which accept the CE Mark." On February 9, 2017, Medovex Corporation announced it had entered into a unit purchase agreement with selected accredited investors. Pursuant to the terms of the agreement, the Company sold an aggregate of 2,905,770 shares and 1,452,885 warrants for gross proceeds of $3,022,000. Each warrant has an initial exercise price of $1.50 per share, subject to adjustment, and is initially exercisable for a period of five years from the date of issuance. Certain officers and directors of Medovex participated in the financing. In conjunction with the closing of the transaction, the Company's previously issued $1,150,000 of senior secured promissory notes has been converted to 165,864 shares of Common Stock and 9399 shares of Series A Preferred Stock and warrants on the same terms as the other investors. Each share of Series A Preferred Stock is convertible into 100 shares of common stock and effectively has the same price of $1.04 per share of Common Stock. In addition to the recent financing transaction, in a transaction filed with the SEC on a Form 8k on December 6, 2016, insiders Jesse Crowne, Steve Gorlin and a third party, completed the purchase of 571,429 shares of the Company's common stock at above then market pricing of $1.75 per share, such that the Company received an aggregate of $1,000,000. On January 3, 2017, the Company announced it had successfully received certification of compliance for its DenerveX System from SGS S.A. a Swiss based multinational testing and certification firm. Compliance testing included electrical safety testing for US, Canada and the European Union. Prior to that on November 3, 2016, the Company announced that it held a successful cadaver lab during NASS 2016. Medical advisory board members Martin Deeg, MD from Stuttgart, Germany, Vik Kapoor, MD from Manchester, England, as well as Gabriel Davila, MD from Colombia, Latin America, highlighted the DenerveX System. Thirty spine surgeons from Europe and Latin America attended the lab, both experiencing and using the device. Jarrett Gorlin, Medovex CEO, commented, "Design, development and commercialization of our flagship patented DenerveX System has been years in the making. It was designed by surgeons for surgeons to be less invasive with faster recovery time than current surgical treatment options, and is designed to provide for a longer lasting treatment solution while offering potential savings to the health care system. We are pleased with the recent completion of the final CE Mark audit meeting conducted February 7-9, 2017 by LNE/GMED, a French-based Notified Body firm." Gorlin concluded, "My personal commitment is no better evidenced than by my recent insider purchases as filed in recent Form 4 filings made with the SEC. In addition, both our Co-founder and VP of Business Development have too made recent insider purchases. I believe it important that we lead by example putting our own money where our mouth is. Recent filings memorializing our own actions affirm our collective commitment and belief in both our team and the opportunity." The DenerveX System consists of the DenerveX device, a single use medical device and the DenerveX Pro-40 Power Generator. DenerveX system is not yet CE marked or FDA cleared and is not yet commercially available. Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


IRVINE, Calif.--(BUSINESS WIRE)--joimax®, the global acting German developer and marketer of technologies and training methods for endoscopic minimally invasive spinal surgery, again exhibited at Chinese Orthopedic Association (COA), which took place Nov. 17th to 20th, 2016 at China National Convention Center in Beijing, China. During the exhibition, the new NASS - joimax® MISS Training Centre was inaugurated. The 18th Chinese Orthopedic Association Annual Meeting and the 11th International Congress of Chinese Orthopedic Association (COA) this year has again taken place in Beijing and was visited by more than 35,000 surgeons who gathered for the latest research results and up-to-date information on technology and clinical progression in orthopedics including spine surgery. joimax® had a major presence with a large booth showing its endoscopic minimally invasive product range. Furthermore on the two major meeting days, 30 lectures from well-known experts were given at its booth. During the COA, the new NASS-joimax® MISS Training Centre in China was inaugurated on Friday Nov. 18th, 2016. The ceremony took place at the joimax® booth together with leaders from the Peking University Third Hospital and members of the NASS Board of Directors. The Chinese market is a very important one for joimax® because Chinese surgeons are highly interested in adopting and deepening their knowledge in endoscopic minimally invasive techniques. joimax® is playing a major role in advanced training and is a driving power in the field of continuing education. “With the launch of TESSYS® ISeeUTM, which has been newly designed especially for the Chinese market, joimax® offers an even more simplified access under facilitated orientation,” says Wolfgang Ries, CEO and founder of joimax®. “The existing TESSYS® trays can furthermore be upgraded with the TESSYS® ISeeUTM supplements,” he continues. Moreover, joimax® also presented its latest product, the newly launched Intracs® Interaoperative Navigation Tracking & Control System for the first time in China. Founded in Karlsruhe, Germany, in 2001, joimax® is the leading developer and marketer of complete systems for endoscopic minimally invasive spinal surgery. With TESSYS® (transforaminal), iLESSYS® (interlaminar) and CESSYS® (cervical) for decompression procedures, MultiZYTE® RT (e.g. for rhizotomy) and with MultiZYTE® SI for SI-Joint therapy or with EndoLIF® and Percusys® for endoscopic minimally-invasive assisted stabilizations, proven endoscopic systems are provided that, together, cover a whole variety of indications. With the newly launched Intracs® system, navigation is now faster, safer and more accurate than ever before using an electromagnetic (EM) field. In procedures for herniated disc, stenosis, pain therapy or spinal stabilization treatment, surgeons utilize joimax® technologies to operate through small incisions - under local or full anesthetic - via tissue and muscle-sparing corridors through natural openings into the spinal canal (e.g. intervertebral foramen, the “Kambin triangle”).


News Article | December 28, 2016
Site: www.prweb.com

In preparation for the 2017 Census of Agriculture, close to one million potential farmers and ranchers will receive the National Agricultural Classification Survey (NACS) this month to help the U.S. Department of Agriculture identify all active farms and ranches in the United States. The result of the NACS will determine who receives a census of agriculture questionnaire next December. The census of agriculture, conducted every five years by the USDA’s National Agricultural Statistics Service (NASS), is the only source of uniform, comprehensive and impartial agricultural data for every county in the nation. Through the census of agriculture, producers are able to demonstrate the value and importance of agriculture, and influence decisions that will shape the future of the industry in this country. “NACS plays an integral role in getting a complete count of U.S. agriculture,” said NASS Census and Survey Division Director Barbara Rater. “We ask everyone who receives the survey to please respond by January 30, so that we can maintain an accurate and comprehensive census of agriculture mailing list. This is an important opportunity. The census of agriculture is the leading source of facts about American agriculture. Farm organizations, businesses, government decision-makers, commodity market analysts, news media, researchers and so many others use census of agriculture data. We are ensuring that every farm and ranch has a voice.” The census of agriculture defines a farm as any place, big or small, traditional or unique, urban garden to vast countryside that produces and sells, or could sell, $1,000 or more of agriculture products within a calendar year. NACS is required by law as part of the census of agriculture. By this same law, all information reported by individuals is protected. It is NASS’ goal to reach and collect data from every beginner and seasoned farmer. NASS will begin data collection for the 2017 Census of Agriculture in late 2017. The census of agriculture is Your Voice, Your Future, Your Opportunity. For more information about NACS and the 2017 Census of Agriculture, visit http://www.agcensus.usda.gov.


News Article | October 28, 2016
Site: www.marketwired.com

NuVasive Expands Integrated Global Alignment Platform to Support All Spinal Procedures; Company Solves Critical OR Need with Technology that Helps OR Staff Reduce Levels of Exposure to Surgical Radiation SAN DIEGO, CA--(Marketwired - October 25, 2016) - NuVasive, Inc. ( : NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the introduction of new spine innovations at the North American Spine Society (NASS) 31st Annual Meeting held October 26-29, 2016 at the Boston Convention and Exhibition Center. NuVasive will showcase the Company's expanded Integrated Global Alignment™ (iGA) platform, now supporting all spinal procedures, including cervical alignment. In addition, the Company will introduce proprietary image enhancement software that allows the surgical staff to significantly reduce exposure to surgical radiation in the operating room (OR), and directly addresses a known safety concern of surgeons and OR staff. iGA is a proprietary, procedurally-integrated digital platform of specialized products designed to help surgeons achieve more precise spinal column alignment. The expanded platform makes NuVasive the first company to offer a solution to address spinal alignment for all spine procedures and provides surgeons an intuitive surgical workflow during pre-, intra- and post-operative that consists of software and hardware. NuVasive is committed to a global approach for assessing, preserving, and restoring spinal alignment in an effort to promote surgical efficiencies, lasting patient outcomes, and improved quality of life. Part of the expanded platform includes the launch of Bendini® OCT, the innovative computer-assisted, rod bending system, which now has the ability to bend spinal rods for occipito-cervico-thoracic (OTC) cases. Bendini OCT is used in combination with NuvaPlanning™ software, integrated into surgical workflow for pre-, intra- and post-operative planning and confirmation, and NuvaMap™ O.R., the industry's first and only real-time intraoperative assessment tool to assess the correction achieved prior to finishing the case. Also, as part of the cervical iGA platform, the Company will be launching the CoRoent® Small Interlock™ Hyperlordotic system, the first anterior cervical interfixated implant designed to treat cervical alignment deformities by offering multiple lordotic options to address patient-specific correction. "Based on the identified clinical need and scientific foundation of driving improved clinical outcomes through optimized global sagittal alignment, we have expanded our iGA platform to now address cervical alignment. Building on the tremendous success the Company has seen with iGA, we are proud to offer the only available solution to address spinal alignment for all spine procedures," said Jason Hannon, NuVasive's president and chief operating officer. "This cutting-edge surgical planning technology enables surgeons to more completely plan for and achieve total sagittal alignment, including for patients suffering from cervical conditions. It represents another step forward in our mission to transform spine surgery." Physicians can exceed their lifetime Occupational Radiation Limit within the first decade of their career. As surgery trends increasingly towards minimally invasive surgery (MIS) due to patient benefits, surgeon familiarity and superior clinical and economical outcomes, radiation exposure to surgeons and OR staff may increase. To directly address this potential barrier to widespread adoption of MIS, NuVasive acquired the LessRay software technology suite from a private company called SafeRay Spine. The LessRay software is designed to be integrated into current surgeon workflow and utilizes an algorithm to drive image registration and enable management of radiation exposure, while maintaining high-quality, intra-operative images on existing C-Arm workflow without loss of visual accuracy. "NuVasive has a strong history of delivering disruptive spine technology. From XLIF to iGA, we continually outpace our peers when addressing unmet clinical and market requirements. Radiation in the OR is a known issue, one that plagues the surgeon, the staff and the patient," said Mr. Hannon. "This proprietary technology is aimed at supporting the surgeon and their staff, transforming their environment to be safer and more productive, while directly addressing one of the leading barriers to adopt MIS without any disruption to their familiar workflow. We see workflow familiarity as a key requirement for broad and rapid adoption of any successful technology platform. "In addition, the technology fits our portfolio of differentiated solutions as a foundational element of our imaging, navigation and surgical automation development strategy. Our unmatched spine platform includes industry-leading hardware, software and services, transforming spine surgery through reproducible clinical and economic outcomes," added Mr. Hannon. NuVasive will showcase and demo its new technologies at NuVasive Booth #1315 on the NASS exhibit floor. The Company will also feature the new BASE™ Interfixated Titanium system, a key addition to the iGA platform. BASE is designed to achieve fusion goals and spinal alignment objectives with precision, innovative functionality and a wide range of implant size and lordosis options. Titanium implants have a proven strength profile compared to that of other materials on the market. The new system offers versatile fixation options with a distinctive locking mechanism and anatomic implant design to help rebuild spinal foundation. NuVasive's participation at NASS includes a series of in-booth presentations and workshops. Visit the Company's website for presentation details. About NuVasive NuVasive, Inc. ( : NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive's highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $811 million in revenues (2015), NuVasive has an approximate 2,200 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com. Forward-Looking Statements NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA™ platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

Loading NASS collaborators
Loading NASS collaborators